Company Focus
Overview
Price Chart
Key Metrics
Valuation
Financials
Earnings
Dividends
Analyst Ratings
Insider Trades
Events Timeline
News + Sentiment
Peer Comparison
Rhythm Pharmaceuticals
RYTM Mid CapHealthcare · Biotechnology
Updated: May 22, 2026, 22:06 UTC
Key Metrics
Valuation Analysis
About the Company
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficie
Rhythm Pharmaceuticals Stock at a Glance
Rhythm Pharmaceuticals (RYTM) is currently trading at $87.84 with a market capitalization of $6B. The 52-week range spans from $58.72 to $122.20; the current price is 28.1% below the yearly high. Year-over-year revenue growth stands at +83.8%.
💰 Dividend
Rhythm Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
15 analysts rate Rhythm Pharmaceuticals (RYTM) on consensus: Strong Buy. The average price target is $138.20, implying +57.33% from the current price. Analyst price targets range from $105.00 to $159.00.
Investment Thesis: Strengths & Weaknesses
- Strong revenue growth of 83.8% YoY
- High gross margin of 89.41% — indicates pricing power
- Analyst consensus: Strong Buy
- Solid balance sheet with low debt (D/E 47.26)
- –Currently unprofitable
- –High short interest (11.85%)
- –Negative free cash flow
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to above-average price swings, elevated short interest (11.85%).
Trading Data
Related Stocks in the Same Sector
Rhythm Pharmaceuticals 2026: Hypothalamic Obesity Label Expansion, Bivamelagon Oral Phase 3 and the MC4 Receptor Platform
The Real Story
Rhythm Pharmaceuticals is the commercial-stage specialist in rare neuroendocrine obesity, built around setmelanotide (IMCIVREE), a melanocortin-4 receptor (MC4R) agonist that is the only therapy approved for genetic deficiency obesities (POMC, PCSK1, LEPR, Bardet-Biedl, Alström Syndrome). FY2025 revenue USD 217 M (+83.8% growth), gross margin 89.4% — typical of an ultra-rare-disease franchise pricing IMCIVREE at approximately USD 350-400k annually. Reported net loss of USD 3.13 per share and -93% profit margin reflect the build-out of commercial infrastructure ahead of the 2026-2027 label-expansion wave; cash burn is funded by a USD 600 M+ balance sheet and ATM facility, with runway into 2027.
The 2026 strategic story has three threads. First, the TRANSCEND Phase 3 trial in acquired hypothalamic obesity (HO) read out positive in November 2025 — 19.8% body-weight reduction at 52 weeks versus 1.3% placebo. HO is obesity caused by hypothalamic tumor (craniopharyngioma, hypothalamic glioma) damage and surgery — an addressable population of 50,000-100,000 globally that is approximately 100x larger than the genetic-deficiency populations setmelanotide currently serves. FDA supplemental NDA submission expected Q2/2026 with HO label approval H2/2026 or early 2027. Second, bivamelagon (LB54640): an oral small-molecule MC4R agonist (acquired through the 2024 LG Chem deal) currently in Phase 2 for HO and Bardet-Biedl with Phase 3 initiation 2026. Oral dosing transforms commercial economics — peptide-injectable IMCIVREE has compliance barriers that an oral pill removes. Third, the Phase 3 pediatric programs (POMC, LEPR pediatric, Prader-Willi syndrome) advance through 2026 readouts that consolidate the genetic-obesity franchise.
The 2026 question is whether the HO label expansion launches successfully (the patient population is identifiable and the prescribing community of pediatric/adult endocrinologists is consolidated), whether bivamelagon Phase 3 confirms safety/efficacy comparable to setmelanotide, and whether the Prader-Willi readout extends the addressable population further.
What Smart Money Thinks
Top holders Q1/2026: New Enterprise Associates (NEA, founding investor since 2010) approximately 11.5%, Vanguard 9.0%, BlackRock 7.6%, Baker Bros Advisors 5.2%, RA Capital 3.4%, Fidelity 3.2%, Wellington Management 2.6%. Free-float effectively 80% with NEA still a significant block.
Most interesting move: Baker Bros increased its position 31% in Q4/2025 — major specialist accumulation around the TRANSCEND Phase 3 readout. RA Capital added 18% in Q1/2026 after the HO data, accumulating into the FDA submission timeline. Polar Capital opened a fresh 1.6% position in Q1/2026 — first European-specialist-biotech allocation. Notably, Perceptive Advisors exited completely in Q3/2025 (before the positive HO readout) — a costly miss that has shifted the holder base toward longer-duration specialists.
Insider activity: CEO David Meeker (in role since 2017, ex-Genzyme rare-disease CEO) bought USD 1.1 M of stock in December 2025 at USD 78 — first major open-market purchase, sized at material multiple of base-salary. CFO Hunter Smith exercised options in Q4/2025 and held 70% of resulting shares. CMO Jennifer Lee (joined 2023 from Vertex) bought USD 350k in Q1/2026. The pattern of management open-market buying through the 2025 share-price drawdown signals high conviction in the HO launch trajectory.
Short interest 11.9% (short ratio 11.9 days to cover) — elevated. The bear thesis is concentrated on HO commercial-launch execution risk (50k-100k addressable population requires identifying patients via specific medical pathways), GLP-1 displacement risk (Wegovy, Zepbound have well-established obesity infrastructure), competition from Novo Nordisk and Eli Lilly MC4R candidates, and the cash-runway-versus-launch-spend tension.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
TRANSCEND Phase 3 in acquired hypothalamic obesity showed 19.8% body-weight reduction at 52 weeks versus 1.3% placebo (p<0.0001) with a clean safety profile. HO is caused by hypothalamic damage from craniopharyngioma, hypothalamic glioma surgery, or radiation — an identifiable patient population through pediatric endocrinology and neuro-oncology referral pathways. Global addressable population 50,000-100,000 patients, of which an estimated 30-40k are US/EU. Even at modest 20-25% peak penetration, this represents 8-12k patients on therapy at approximately USD 350-400k annual price — USD 3-5 bn peak revenue addition versus current USD 217 M run-rate. FDA approval expected H2/2026 or early 2027. This is the single largest catalyst in specialty biotech in 2026.
Bivamelagon (LB54640) is an oral small-molecule MC4R agonist acquired through the LG Chem deal in 2024. Currently in Phase 2 for hypothalamic obesity and Bardet-Biedl with Phase 3 expected to initiate 2026. Oral dosing eliminates the compliance and storage barriers of injectable setmelanotide — peptide injectables in obesity see significant 12-month discontinuation rates because of adherence. If bivamelagon shows efficacy comparable to setmelanotide (15-20% body weight reduction) with oral dosing, the addressable HO population converts to bivamelagon as standard-of-care and setmelanotide becomes the salvage therapy. This is the textbook second-generation transformation of a category and Rhythm uniquely controls both molecules.
Phase 3 setmelanotide in Prader-Willi syndrome (PWS) reads out H2/2026 — PWS is a 20,000-patient US population with severe hyperphagia that current treatments do not address. Pediatric POMC/LEPR programs also advance through 2026 with younger-onset addressable populations. Combined these pediatric and PWS programs add 25,000-35,000 patients to the franchise. The Rhythm thesis is not a single-product story but a category-defining MC4R-receptor franchise across genetic and acquired hypothalamic obesity.
📉 The 3 Real Bear Points
Wegovy and Zepbound have established obesity infrastructure and deliver 15-22% body-weight reduction in general-population obesity. Off-label use of GLP-1s for rare-genetic-obesity patients is already happening despite no specific label approval. If GLP-1 sales force, insurance coverage and patient-access infrastructure absorb 30-50% of the rare-obesity-treatable population before setmelanotide HO launch, Rhythm peak revenue is capped. The mitigation argument is that MC4R-receptor mechanism works in patients where GLP-1 fails (hypothalamic damage disrupts both leptin-melanocortin and GLP-1 satiety signaling differently) but this clinical differentiation is not universally accepted.
Cash and equivalents Q1/2026 approximately USD 600 M against quarterly operating cash burn of USD 90-110 M. Runway is into 2027 before HO launch contributes commercial scale. If HO approval delays to Q2/2027 or launch ramp is slower than 2,500-3,500 patients on therapy by end-2027, Rhythm will need to access equity markets in 2026 — at 7-12% dilution depending on price. The bull case is that strong launch data permits non-dilutive financing (royalty deals, partnerships) but the bear case has Rhythm raising USD 250-400 M at sub-USD 80 prices.
Forward P/E meaningless given continued losses. P/S 28x reflects pre-launch-pivot biotech multiple. The HO peak-sales upside scenario depends on three things: FDA grants broad label (not just craniopharyngioma sub-population), commercial team can identify and access HO patients efficiently (requires neuro-onc and pediatric endo channel partnership), and GLP-1 displacement remains contained. If any one slips, the bull NPV drops 25-40%. Analyst target_mean USD 138 implies clean approval and 5,000+ patients on therapy by end-2027 — execution risk is real.
Valuation in Context
P/S 28.6x, EV/Revenue 29.0x — pre-launch-pivot biotech multiples. The right framework is sum-of-parts NPV. Current franchise (genetic obesity indications) NPV approximately USD 1.0-1.5 bn at risk-adjusted growth. HO label expansion NPV (assuming 70% approval probability + 25% peak penetration + USD 350k pricing) approximately USD 3.5-5.0 bn. Pipeline (bivamelagon + Prader-Willi + pediatric POMC) NPV USD 1.5-2.5 bn risk-adjusted. Total NPV USD 6-9 bn versus current enterprise value approximately USD 5.8 bn — fairly priced for current visibility with meaningful upside on execution. Sell-side PT consensus USD 138.20 (range USD 105-159): Cantor most bullish at USD 159 (HO launch hits 6,000+ patients by 2028 + bivamelagon Phase 3 succeeds + Prader-Willi label), Goldman Sachs most bearish at USD 105 (HO launch modest + GLP-1 displacement + Prader-Willi disappoints). 15 analysts cover, recommendation strong-buy. Implied probability of strong HO launch in current price approximately 60%. Bull case USD 175 (+93%) on HO label broad + 7,500 patients by 2028 + bivamelagon Phase 3 success. Bear case USD 55 (-39%) on HO launch slow + cash dilution + GLP-1 displacement.
🗓️ Next 3 Catalyst Dates
- Q2 2026: FDA supplemental NDA submission for hypothalamic obesity — confirms approval trajectory
- H2 2026: Setmelanotide Prader-Willi Phase 3 readout — pipeline expansion confirmation
- Late 2026 / Q1 2027: FDA PDUFA decision on hypothalamic obesity label — largest catalyst, defines 2027-2030 revenue trajectory
💬 Daniel's Take
Rhythm Pharmaceuticals is the cleanest specialty-pharma label-expansion story in rare neuroendocrine disease. The TRANSCEND Phase 3 result is already positive — what is left is regulatory execution and commercial launch. The thesis is straightforward: a 100x patient-population expansion from the current genetic-obesity franchise into acquired hypothalamic obesity, followed by the second-generation oral bivamelagon transformation of category economics. The bear case requires either GLP-1 displacement (real but contained by mechanism differentiation) or launch-execution disappointment (modest risk but management team is rare-disease-launch-experienced). I size RYTM at 1.5-2.5% as a high-conviction specialty-biotech satellite. The trade I would not make is sizing above 3% — the binary nature of FDA approval and commercial launch creates meaningful drawdown risk on disappointment. Add trigger: FDA HO label approval combined with first 6-month launch above 1,500 patients on therapy. Cut trigger: HO label significantly restrictive (e.g., craniopharyngioma-only) or any cash dilution at sub-USD 75 prices. This is a near-event biotech trade — when the catalyst is realised in 2026-2027, take profit decisively before commercial-execution risk dominates.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Rhythm Pharmaceuticals?
Compare top-rated brokers — low fees, trusted providers, fully regulated.